Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4- isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: Interim results from phase III, extension study 307

Epilepsia

Volumn 54, Issue 1, 2013, Pages 126-134

  Krauss, Gregory L ^a,i   Perucca, Emilio ^b   Ben Menachem, Elinor ^c   Kwan, Patrick ^d,e   Shih, Jerry J ^f   Squillacote, David ^g   Yang, Haichen ^g   Gee, Michelle ^h   Zhu, Jin ^g   Laurenza, Antonio ^g  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF PAVIA   (Italy)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f MAYO CLINIC   (United States)

^g EISAI INC   (United States)

^h EISAI CO LTD   (Japan)

ⁱ NONE   (United States)

Author keywords

Long term; Open label; Partial epilepsy; Perampanel; Safety; Amino 3 hydroxy 5 methyl 4 isoxazolepropionic acid

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID RECEPTOR ANTAGONIST; PERAMPANEL; PLACEBO; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; AGGRESSION; ANXIETY; ARTICLE; ATAXIA; BALANCE DISORDER; CHILD; CONFUSION; CONVULSION; DEPRESSION; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FALLING; FATIGUE; FEMALE; FOCAL EPILEPSY; FOLLOW UP; GAIT DISORDER; HUMAN; IRRITABILITY; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPHIL COUNT; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; SCHOOL CHILD; SEIZURE; SIDE EFFECT; SOMNOLENCE; SUICIDAL IDEATION; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT GAIN;

EID: 84872078864     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2012.03648.x     Document Type: Article

References (17)

1. Beydoun A, Sachdeo RC, Kutluay E, McCague K, D'Souza J,. (2003) Sustained efficacy and long-term safety of oxcarbazepine: one-year open-label extension of a study in refractory partial epilepsy. Epilepsia 44: 1160-1165.
2. During MJ, Spencer DD,. (1993) Extracellular hippocampal glutamate and spontaneous seizure in the conscious human brain. Lancet 341: 1607-1610.
3. French JA,. (2007) Refractory epilepsy: clinical overview. Epilepsia 48 (Suppl. 1): 3-7.
4. French J, Krauss GL, Biton V, Squillacote D, Yang H, Laurenza A, Kumar D, Rogawski MA,. (2012a) Adjunctive perampanel for refractory partial-onset seizures: randomized Phase III study 304. Neurology [Epub ahead of print].
5. French JA, Krauss GL, Steinhoff BJ, Squillacote D, Yang H, Kumar D, Laurenza A,. (2012b) Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia In press.
6. Halász P, Cramer JA, Hodoba D, Czlonkowska A, Guekht A, Maia J, Elger C, Almeida L, Soares da Silva P,. (2010) Long-term efficacy and safety of eslicarbazepine acetate: results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsy. Epilepsia 51: 1963-1969.
7. Hanada T, Hashizume Y, Tokuhara N, Takenaka O, Kohmura N, Ogasawara A, Hatakeyama S, Ohgoh M, Ueno M, Nishizawa Y,. (2011) Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia 52: 1331-1340.
8. Krauss GL, Bar M, Biton V, Klapper JA, Rektor I, Vaiciene-Magistris N, Squillacote D, Kumar D,. (2012a) Tolerability and safety of perampanel: two randomized dose-escalation studies. Acta Neurol Scand 125: 8-15.
9. Krauss GL, Serratosa JM, Villanueva V, Endziniene M, Hong Z, French J, Yang H, Squillacote D, Edwards HB, Zhu J, Laurenza A,. (2012b) Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology 78: 1408-1415.
10. Meldrum BS, Rogawski MA,. (2007) Molecular targets for antiepileptic drug development. Neurotherapeutics 4: 18-61.
11. Perucca E, Tomson T,. (2011) The pharmacological treatment of epilepsy in adults. Lancet Neurol 10: 446-456.
12. Perucca E, French J, Bialer M,. (2007) Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurol 6: 793-804.
13. Rogawski MA,. (2011) Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr 11: 56-63.
14. Rogawski MA, Donevan SD,. (1999) AMPA receptors in epilepsy and as targets for antiepileptic drugs. Adv Neurol 79: 947-963.
15. St Louis EK,. (2009) Minimizing AED adverse effects: improving quality of life in the interictal state in epilepsy care. Curr Neuropharmacol 7: 106-114.
16. Wroe SJ, Yeates AB, Marshall A,. (2008) Long-term safety and efficacy of zonisamide in patients with refractory partial-onset epilepsy. Acta Neurol Scand 118: 87-93.
17. Zheng H, Patterson C, Berthoud HR,. (2002) Behavioral analysis of anorexia produced by hindbrain injections of AMPA receptor antagonist NBQX in rats. Am J Physiol Regul Integr Comp Physiol 282: R147-R155.